INVA

Innoviva Inc. (INVA) | Rumor.io

Innoviva

INVA

Attention (50-day avg)0%

Attention rank (50-day avg)#4,098

Bullish sentiment (50-day avg)100%

Price to earnings ratio4.82

Market capitalization1.5B

Earnings per share4.31

Dividend yield (TTM)4.71%

Revenue (annual)411.3M

Net income (annual)271.2M

Social

What share of all stock conversation is about INVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Mar 5

INVA's parent company, Innoviva, reported total revenue of $411.3M for FY2025.
Net product sales for Innoviva increased 77% to $172.1M in FY2025.
Innoviva's net income for FY2025 was $271.2M, with basic EPS of $4.02.

Generated by AI

Sentiment

Of the messages about INVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98% -0.67
Bearish	—	—	—	2% +0.67

Apr 3

$INVA is a solid long-term hold due to its strong team and product, with a quiet revenue share model that scales as the ecosystem grows.
The company is thriving in a bad market, with real integrations and real value to the blockchain, and is expanding its operations.
$INVA is undervalued and has a great pick for the long term, with a strong focus on building and a long-term perspective that sets it apart from other projects.

Generated by AI

Topics

Of the messages about INVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	32.59%
Analysts	0%	0%	0%	25.89%
Controversies	0%	0%	0%	4.91%
Earnings	0%	0%	0%	2.23%
Macro	0%	0%	0%	22.77%
Technical Analysis	0%	0%	0%	11.61%

Earnings· Jul 26

Innoviva, Inc. ($INVA) missed earnings estimates by $0.06 and revenue estimates.
The company reported FQ2 earnings of 49c EPS and $67.09M in revenues.
$INVA missed the Estimize EPS consensus by 12c and the Estimize revenue consensus by $6.14M.

Announcements· Jan 17

Innovia Trust ($INVA) partners with Assure DeFi to enhance project verification, security, and credibility, integrating KYC, audits, and verification badges.
The partnership brings new possibilities for the $INVA community, including enhanced KYC and audit capabilities, an expanded network, and improved project verification.
Innovia Trust's cutting-edge tech, including Bubble Maps and EchoConnect, is revolutionizing blockchain security and transparency, empowering users to explore new possibilities.

Generated by AI

Community

Of the messages about INVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	28.23%
Newcomers	0%	0%	0%	71.77%

Regulars· Jul 11

Innoviva to acquire La Jolla Pharmaceutical Company for $6.23 per share, representing an 83.8% premium and valuing the company at $149 million.
The acquisition is expected to result in an arbitrage yield of 10.6% and an implied 97% odds of success.
The acquisition has been completed, with Innoviva acquiring La Jolla Pharmaceutical Company for $5.95 per share, including incremental cash proceeds.

Newcomers· Apr 18

Innoviva, Inc.'s Sulbactam-Durlobactam has been recommended for approval by the US FDA panel for treating hospital-acquired pneumonia and ventilator-associated pneumonia caused by susceptible strains of Acinetobacter baumannii-carbapenemase.
The treatment is aimed at addressing the growing concern of antibiotic resistance, with Innoviva's drug potentially offering a new solution for this pressing issue.
The FDA's recommendation is a significant step forward for Innoviva, Inc., as it brings the company's asset closer to being approved for use in the US market.

Generated by AI

News

Innoviva at H.C. Wainwright conference: growth shifts to specialty drugs

15d agoInvesting.com

Innoviva at Cantor conference: growth bets beyond COPD royalties

19d agoInvesting.com

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif., September 02, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:

28d agoYahoo Finance

Cantor Fitzgerald reiterates Innoviva stock rating at overweight

1mo agoInvesting.com

Three Innoviva therapies named finalists for Prix Galien award

1mo agoInvesting.com

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

WALTHAM, Mass., August 11, 2026--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics produ

1mo agoYahoo Finance

Also Discussed

Investors talking about INVA also mention

#	Name	Attention
1	Theravance Biopharma Inc.TBPH	0%new
2	Relative Sentiment Tactical Allocation FundMOOD	0%0
3	Essent Group Ltd.ESNT	0%0
4	Global X Guru Index ETFGURU	0.02%new
5	GoldMining Inc.GLDG	0%new
6	Allegiant Travel CoALGT	0%new
7	SNPO - Snap One Holdings Corp.	——
8	MiMedx Group, Inc.MDXG	0%0
9	International Bancshares Corp.IBOC	0%0
10	Talkspace Inc.TALK	0%0

Innoviva Inc.

Healthcare
Biotechnology

Innoviva Inc. is a diversified biopharmaceutical company focused on healthcare assets, royalty streams, and specialty therapeutics. Its core business includes a royalty portfolio tied to respiratory medicines partnered with GSK, along with ownership and management of operating healthcare businesses. Through Innoviva Specialty Therapeutics, the company develops and commercializes treatments in critical care and infectious disease, including antimicrobial and hospital-focused therapies. Innoviva also maintains strategic investments in healthcare assets and related life sciences businesses, giving it a broader role across drug development, licensing, and asset management. Headquartered in Burlingame, California, Innoviva Inc. combines recurring royalty income with product-focused operations, positioning it as a multi-asset participant in the biopharmaceutical market.

Website

Location

1350 Old Bayshore Highway

Burlingame, CA, 94010

United States

Social

What share of all stock conversation is about INVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Mar 5

INVA's parent company, Innoviva, reported total revenue of $411.3M for FY2025.
Net product sales for Innoviva increased 77% to $172.1M in FY2025.
Innoviva's net income for FY2025 was $271.2M, with basic EPS of $4.02.

Generated by AI

Sentiment

Of the messages about INVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98% -0.67
Bearish	—	—	—	2% +0.67

Apr 3

$INVA is a solid long-term hold due to its strong team and product, with a quiet revenue share model that scales as the ecosystem grows.
The company is thriving in a bad market, with real integrations and real value to the blockchain, and is expanding its operations.
$INVA is undervalued and has a great pick for the long term, with a strong focus on building and a long-term perspective that sets it apart from other projects.

Generated by AI

Topics

Of the messages about INVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	32.59%
Analysts	0%	0%	0%	25.89%
Controversies	0%	0%	0%	4.91%
Earnings	0%	0%	0%	2.23%
Macro	0%	0%	0%	22.77%
Technical Analysis	0%	0%	0%	11.61%

Earnings· Jul 26

Innoviva, Inc. ($INVA) missed earnings estimates by $0.06 and revenue estimates.
The company reported FQ2 earnings of 49c EPS and $67.09M in revenues.
$INVA missed the Estimize EPS consensus by 12c and the Estimize revenue consensus by $6.14M.

Announcements· Jan 17

Innovia Trust ($INVA) partners with Assure DeFi to enhance project verification, security, and credibility, integrating KYC, audits, and verification badges.
The partnership brings new possibilities for the $INVA community, including enhanced KYC and audit capabilities, an expanded network, and improved project verification.
Innovia Trust's cutting-edge tech, including Bubble Maps and EchoConnect, is revolutionizing blockchain security and transparency, empowering users to explore new possibilities.

Generated by AI

Community

Of the messages about INVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	28.23%
Newcomers	0%	0%	0%	71.77%

Regulars· Jul 11

Innoviva to acquire La Jolla Pharmaceutical Company for $6.23 per share, representing an 83.8% premium and valuing the company at $149 million.
The acquisition is expected to result in an arbitrage yield of 10.6% and an implied 97% odds of success.
The acquisition has been completed, with Innoviva acquiring La Jolla Pharmaceutical Company for $5.95 per share, including incremental cash proceeds.

Newcomers· Apr 18

Innoviva, Inc.'s Sulbactam-Durlobactam has been recommended for approval by the US FDA panel for treating hospital-acquired pneumonia and ventilator-associated pneumonia caused by susceptible strains of Acinetobacter baumannii-carbapenemase.
The treatment is aimed at addressing the growing concern of antibiotic resistance, with Innoviva's drug potentially offering a new solution for this pressing issue.
The FDA's recommendation is a significant step forward for Innoviva, Inc., as it brings the company's asset closer to being approved for use in the US market.

Generated by AI

Innoviva

Social

Mar 5

Apr 3

Earnings· Jul 26

Announcements· Jan 17

Regulars· Jul 11

Newcomers· Apr 18

Innoviva at H.C. Wainwright conference: growth shifts to specialty drugs

Innoviva at Cantor conference: growth bets beyond COPD royalties

Innoviva to Participate in Upcoming Investor Conferences

Cantor Fitzgerald reiterates Innoviva stock rating at overweight

Three Innoviva therapies named finalists for Prix Galien award

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Also Discussed

Innoviva Inc.

Company Information

Location

Innoviva at H.C. Wainwright conference: growth shifts to specialty drugs

Innoviva at Cantor conference: growth bets beyond COPD royalties

Innoviva to Participate in Upcoming Investor Conferences

Cantor Fitzgerald reiterates Innoviva stock rating at overweight

Three Innoviva therapies named finalists for Prix Galien award

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Also Discussed

Social

Mar 5

Apr 3

Earnings· Jul 26

Announcements· Jan 17

Regulars· Jul 11

Newcomers· Apr 18